Prandin Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Novo Nordisk's diabetes therapy Prandin (repaglinide) was filed Feb. 10, according to FDA's April 19 updated list of filings